PAMELA BLATKIEWICZ: Open Payments
NPI 1669962304 · MOUNT LAUREL, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,293 in 95 payments from 12 companies in 2025. Trend: 2023 $1,159 · 2024 $1,217 · 2025 $2,293
Food & beverage: $2,293
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 15 | $358 |
| Ardelyx, Inc. | 19 | $348 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $324 |
| ABBVIE INC. | 10 | $318 |
| Janssen Biotech, Inc. | 9 | $301 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $156 |
| Celltrion USA Inc. | 4 | $154 |
| Lilly USA, LLC | 3 | $145 |
| Regeneron Healthcare Solutions, Inc. | 6 | $106 |
| Novo Nordisk Inc | 1 | $35 |
Products named: DUPIXENT, IBSRELA, XIFAXAN, TREMFYA, ENTYVIO, ZYMFENTRA, ZEPBOUND, OMVOH.
Industry payments across NJ — which companies pay providers there.
